# Urine Metabolites in the Diagnosis of Disease

> **NCT06710067** · — · RECRUITING · sponsor: **Luventix, Inc.** · enrollment: 1250 (estimated)

## Conditions studied

- Colorectal Cancer
- Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
- Crohn Disease
- Celiac Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06710067
- **Lead sponsor:** Luventix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-09
- **Final completion:** 2026-09
- **Target enrollment:** 1250 (ESTIMATED)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06710067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06710067, "Urine Metabolites in the Diagnosis of Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06710067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*